Launch of New J&J Asthma Treatment by 2024? | Binary | | | 7 months ago | |
Completion of J&J Acquisition of Proteologix by June 2024? | Binary | | | 7 months ago | |
FDA Approval of J&J TSLP/IL13 Bispecific by End of 2024? | Binary | | | 7 months ago | |
Will Johnson & Johnson's stock price be higher one month after the acquisition announcement? | Binary | | | 7 months ago | |
Will the acquisition of Proteologix by Johnson & Johnson be approved by regulatory bodies by the end of 2024? | Binary | | | 7 months ago | |
Will Johnson & Johnson achieve the additional milestone payment within one year of acquiring Proteologix? | Binary | | | 7 months ago | |
Future Structural Role of Proteologix in J&J by Mid-2025 | Categorical | | | 7 months ago | |
Performance of J&J Stock One Year After Proteologix Acquisition | Categorical | | | 7 months ago | |
What will be the outcome of the phase 1 trials for Johnson & Johnson's TSLP targeting asset within 18 months of acquiring Proteologix? | Categorical | | | 7 months ago | |
What will be the impact of the Proteologix acquisition on Johnson & Johnson's market share in atopic dermatitis treatment by the end of 2025? | Categorical | | | 7 months ago | |
How will Johnson & Johnson's new bispecific immunology medications perform in the market two years after launch? | Categorical | | | 7 months ago | |
J&J Global Immunology Market Ranking by 2025 | Categorical | | | 7 months ago | |
